Skip to main content
. Author manuscript; available in PMC: 2024 Mar 2.
Published in final edited form as: Cancer Chemother Pharmacol. 2023 Mar 2;91(3):281–290. doi: 10.1007/s00280-023-04511-0

Table 3.

Toxicity summary for treatment-related toxicities

Category Adverse event All grades
Number of patients
(%)
Grades 3–4
Number of
patients (%)
Cardiac Prolonged QTc 8 (40) 0 (0)
Gastrointestinal Anorexia 12 (60) 0 (0)
Abdominal pain 4 (20) 0 (0)
Diarrhea 16 (80) 3 (15)
Mucositis 4 (20) 1 (5)
Nausea 16 (80) 1 (5)
Vomiting 12 (60) 1 (5)
General Fatigue 10 (50) 3 (15)
Hematologic White blood cell decreased 4 (20) 4 (20)
Investigations Weight loss 9 (45) 0 (0)
Metabolic Dehydration 9 (45) 1 (5)
Musculoskeletal Generalized muscle weakness 6 (30) 0 (0)
Neurologic Dizziness 4 (20) 0 (0)
Dysgeusia 10 (50) 0 (0)
Vascular Flushing 4 (20) 0 (0)

Includes toxicities with at least 20% incidence